Using tenecteplase for acute ischemic stroke: What is the hold up?

Tony Zitek, Ramsey Ataya, Isabel Brea

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Alteplase is the only Food and Drug Administration-approved intravenous (IV) thrombolytic medication for acute ischemic stroke. However, multiple recent studies comparing tenecteplase and alteplase suggest that tenecteplase is at least as efficacious as alteplase with regards to neurologic improvement. When given at 0.25 milligrams per kilogram (mg/kg), tenecteplase may have less bleeding complications than alteplase as well. This narrative review evaluates the literature and addresses the practical issues with regards to the use of tenecteplase versus alteplase for acute ischemic stroke, and it recommends that physicians consider tenecteplase rather than alteplase for thrombolysis of acute ischemic stroke.

Original languageEnglish (US)
Pages (from-to)199-202
Number of pages4
JournalWestern Journal of Emergency Medicine
Volume21
Issue number2
DOIs
StatePublished - 2020

All Science Journal Classification (ASJC) codes

  • Emergency Medicine

Fingerprint

Dive into the research topics of 'Using tenecteplase for acute ischemic stroke: What is the hold up?'. Together they form a unique fingerprint.

Cite this